Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Aug 21:2024.08.20.24312181.
doi: 10.1101/2024.08.20.24312181.

Genetics of posttraumatic stress disorder and cardiovascular conditions using Life's Essential 8, Electronic Health Records, and Heart Imaging

Affiliations

Genetics of posttraumatic stress disorder and cardiovascular conditions using Life's Essential 8, Electronic Health Records, and Heart Imaging

Jie Shen et al. medRxiv. .

Abstract

Background: Patients with post-traumatic stress disorder (PTSD) experience higher risk of adverse cardiovascular (CV) outcomes. This study explores shared loci, and genes between PTSD and CV conditions from three major domains: CV diagnoses from electronic health records (CV-EHR), cardiac and aortic imaging, and CV health behaviors defined in Life's Essential 8 (LE8).

Methods: We used genome-wide association study (GWAS) of PTSD (N=1,222,882), 246 CV diagnoses based on EHR data from Million Veteran Program (MVP; N=458,061), UK Biobank (UKBB; N=420,531), 82 cardiac and aortic imaging traits (N=26,893), and GWAS of traits defined in the LE8 (N = 282,271 ~ 1,320,016). Shared loci between PTSD and CV conditions were identified using local genetic correlations (rg), and colocalization (shared causal variants). Overlapping genes between PTSD and CV conditions were identified from genetically regulated proteome expression in brain and blood tissues, and subsequently tested to identify functional pathways and gene-drug targets. Epidemiological replication of EHR-CV diagnoses was performed in AllofUS cohort (AoU; N=249,906).

Results: Among the 76 PTSD-susceptibility risk loci, 33 loci exhibited local rg with 45 CV-EHR traits (|rg|≥0.4), four loci with eight heart imaging traits(|rg|≥0.5), and 44 loci with LE8 factors (|rg|≥0.36) in MVP. Among significantly correlated loci, we found shared causal variants (colocalization probability > 80%) between PTSD and 17 CV-EHR (in MVP) at 11 loci in MVP, that also replicated in UKBB and/or other cohorts. Of the 17 traits, the observational analysis in the AoU showed PTSD was associated with 13 CV-EHR traits after accounting for socioeconomic factors and depression diagnosis. PTSD colocalized with eight heart imaging traits on 2 loci and with LE8 factors on 31 loci. Leveraging blood and brain proteome expression, we found 33 and 122 genes, respectively, shared between PTSD and CVD. Blood proteome genes were related to neuronal and immune processes, while the brain proteome genes converged on metabolic and calcium-modulating pathways (FDR p <0.05). Drug repurposing analysis highlighted DRD2, NOS1, GFAP, and POR as common targets of psychiatric and CV drugs.

Conclusion: PTSD-CV comorbidities exhibit shared risk loci, and genes involved in tissue-specific regulatory mechanisms.

Keywords: Brain; Cardiovascular Disease; GWAS; Heart; Life’s Essential 8; PTSD; electronic health records.

PubMed Disclaimer

Conflict of interest statement

7COMPETING INTERESTS Dr. Polimanti reports a research grant from Alkermes outside the scope of this study. Drs. Polimanti and Gelernter are paid for their editorial work on the journal Complex Psychiatry. Dr. Gelernter is named as an inventor on PCT patent application no. 15/878,640 entitled “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. Dr. Stein has in the past 3 years received consulting income from Actelion, Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, Boehringer Ingelheim, Bionomics, BioXcel Therapeutics, Clexio, Delix Pharmaceuticals, EmpowerPharm, Engrail Therapeutics, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and Roche/Genentech; has stock options in Oxeia Biopharmaceuticals and EpiVario; and has been paid for editorial work on Depression and Anxiety (Editor-in-Chief), Biological Psychiatry (Deputy Editor), and UpToDate (Co-Editor-in-Chief for Psychiatry).Dr. O’Donnell an employee of Novartis Pharmaceuticals). Dr. Koller is the founder and CEO of EndoCare Therapeutics, but the company conducts research unrelated to the present study. The other authors declare no competing interests.

Figures

Figure 1:
Figure 1:. Study Design:
We investigated loci shared between posttraumatic stress disorder (PTSD) and cardiovascular (CV)-related traits, including American Heart Association’s Life Essential 8 factors, CV diagnoses derived from electronic health records (EHR), and cardiac imaging phenotypes. After identifying genetically correlated loci between PTSD and CV conditions, we investigated shared causal variants. For the EHR-based CV diagnoses, we performed replication of shared causal variants in UK Biobank and a follow-up analysis in All of US Research Program. The traits with evidence of PTSD-CV shared causal variants were tested with respect to tissue-specific transcriptomic and proteomic profiles. The overlapping genes were investigated for overrepresented pathways and drug targets.
Figure 2:
Figure 2:. Local Genetic Correlation between PTSD and CV conditions:
Matrix plot of local genetic correlation between PTSD and conditions grouped by their CV category (left y-axis); the EHR-based CV definitions (i.e., phecodes) are from Million Veteran Program. The x-axis shows loci as cytobands grouped by chromosomes. The positive correlation is denoted in orange, cyan indicates negative correlation, and the size of the squares corresponds to the magnitude of the genetic correlation.
Figure 3:
Figure 3:. Shared causal variants between PTSD and CV conditions:
A) Top. The x-axis shows colocalization probability(different LD-linked causal variants-H3 hypothesis; same causal variant – H4 hypothesis), and y-axis is marked with CV conditions. between PTSD and CV conditions based on colocalization. A subset of 11 loci that replicated for EHR-derived diagnosis are indicated with a blue line. The shared causal variants based on H4 hypothesis are labelled and their nearest genes are in parenthesis. We highlight genes at each locus that had colocalization evidence with molecular profiles (gene/splicing/proteome expression) and CV conditions (Supplementary Table S7); B) Bottom. A stacked bar plot showing number of traits (y-axis) observed at each locus, marked as cytoband and position range in base pairs (x-axis). The traits are grouped into three CV categories.
Figure 3:
Figure 3:. Shared causal variants between PTSD and CV conditions:
A) Top. The x-axis shows colocalization probability(different LD-linked causal variants-H3 hypothesis; same causal variant – H4 hypothesis), and y-axis is marked with CV conditions. between PTSD and CV conditions based on colocalization. A subset of 11 loci that replicated for EHR-derived diagnosis are indicated with a blue line. The shared causal variants based on H4 hypothesis are labelled and their nearest genes are in parenthesis. We highlight genes at each locus that had colocalization evidence with molecular profiles (gene/splicing/proteome expression) and CV conditions (Supplementary Table S7); B) Bottom. A stacked bar plot showing number of traits (y-axis) observed at each locus, marked as cytoband and position range in base pairs (x-axis). The traits are grouped into three CV categories.
Figure 4:
Figure 4:. Shared genes and pathways between PTSD and CV conditions based on proteome-wide associations:
Distribution of z-scores across significant PWAS genes between PTSD and CV conditions using A) brain proteome in blue and B) blood proteome in red. Genes are grouped based on two blood-based proteome panels/brain-based panel (y-axis) and respective CV conditions (x-axis). Significant genes are shown as red (blood) or blue (brain) triangles, wherein triangles facing up and down represent positive and negative z-scores, respectively.
Figure 5:
Figure 5:. Comparing common drugs and their gene-targets between PTSD and CV conditions:
This Sankey plot shows the psychiatric drugs and their classes (first & second panel) that target genes – DRD2, GFAP,POR and NOS1 (third panel), which are also targeted by CV drugs (third panel) and their corresponding CV categories (fourth & fifth panel) (see Supplementary Tables for more details).

References

    1. Vaduganathan M, Mensah GA, Turco JV, Fuster V and Roth GA. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J Am Coll Cardiol. 2022;80:2361–2371. - PubMed
    1. Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, Grandner MA, Lavretsky H, Perak AM, Sharma G and Rosamond W. Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. Circulation. 2022;146:e18–e43. - PMC - PubMed
    1. Polimanti R and Wendt FR. Posttraumatic stress disorder: from gene discovery to disease biology. Psychol Med. 2021;51:2178–2188. - PMC - PubMed
    1. Jacquet-Smailovic M, Brennsthul M-J, Denis I, Kirche A, Tarquinio C and Tarquinio C. Relationship between Post-traumatic Stress Disorder and subsequent myo cardial infarction: a systematic review and meta-analysis. Journal of Affective Disorders. 297:525–535. - PubMed
    1. Sumner JA, Kubzansky LD, Roberts AL, Gilsanz P, Chen Q, Winning A, Forman JP, Rimm EB and Koenen KC. Post-traumatic stress disorder symptoms and risk of hypertension over 22 years in a large cohort of younger and middle-aged women. Psychol Med. 46:3105–3116. - PMC - PubMed

Publication types

LinkOut - more resources